Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trial
Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.
Read the full story at Forbes - Business →
Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.
Read the full story at Forbes - Business →